# AML Expressive Writing

> **NCT04006496** · NA · TERMINATED · sponsor: **Duke University** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BEHAVIORAL:** Expressive Writing Coaching

## Key facts

- **NCT ID:** NCT04006496
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-04
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-19
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Recruitment issues due to COVID-19 pandemic.
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006496, "AML Expressive Writing". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04006496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*